By its questions, which it is appropriate to examine together, the referring court essentially asks whether there is an abuse of a dominant position contrary to Article 82 EC if a pharmaceuticals company occupying such a position on the national market for certain medicinal products refuses to meet orders sent to it by wholesalers on
Oma küsimustega, mida on sobilik uurida koos, soovib eelotsusetaotluse esitanud kohus sisuliselt teada saada, kas asjaolu, et siseriiklikul turul teatud ravimite osas valitsevat seisundit omav ravimitootja keeldub temale ravimite hulgimüüjate poolt esitatud tellimusi täitmast, sest need hulgimüüjad tegelevad nimetatud ravimite